Lineage Cell Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Lineage Cell Therapeutics, Inc. (LCTX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.07M, a 61.34% decline year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.73M, a 14.85% increase year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $6.61M, a 130.40% increase year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.68M, a 2.59% decline year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $14.56M, a 53.24% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $9.50M, a 6.19% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $8.95M, a 39.16% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $14.70M, a 238.70% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.07M 10-Q · filed 2026-08-06 | $2.79M 10-Q · filed 2026-08-06 | $9.40M derived: sum of 3 quarters · filed 2026-08-06 | $13.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.73M 10-Q · filed 2026-05-12 | $8.33M derived: sum of 2 quarters · filed 2026-05-12 | $12.01M derived: sum of 3 quarters · filed 2026-05-12 | $14.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $10.29M derived: sum of 2 quarters · filed 2026-03-05 | $13.05M derived: sum of 3 quarters · filed 2026-08-06 | $14.56M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.68M 10-Q · filed 2025-11-06 | $6.45M derived: sum of 2 quarters · filed 2026-08-06 | $7.95M 10-Q · filed 2025-11-06 | $10.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.77M 10-Q · filed 2026-08-06 | $4.27M 10-Q · filed 2026-08-06 | $7.13M derived: sum of 3 quarters · filed 2026-08-06 | $10.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-12 | $4.37M derived: sum of 2 quarters · filed 2026-05-12 | $8.15M derived: sum of 3 quarters · filed 2026-05-12 | $9.56M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.65M derived: sum of 2 quarters · filed 2026-03-05 | $8.05M derived: sum of 3 quarters · filed 2026-03-05 | $9.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.78M 10-Q · filed 2025-11-06 | $5.19M derived: sum of 2 quarters · filed 2025-11-06 | $6.63M 10-Q · filed 2025-11-06 | $8.72M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.41M 10-Q · filed 2025-08-12 | $2.85M 10-Q · filed 2025-08-12 | $4.94M derived: sum of 3 quarters · filed 2025-08-12 | $6.19M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-13 | $3.53M derived: sum of 2 quarters · filed 2025-05-13 | $4.78M derived: sum of 3 quarters · filed 2025-05-13 | $8.00M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $3.33M derived: sum of 2 quarters · filed 2025-03-10 | $6.56M derived: sum of 3 quarters · filed 2025-03-10 | $8.95M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.25M 10-Q · filed 2024-11-14 | $4.47M derived: sum of 2 quarters · filed 2024-11-14 | $6.86M 10-Q · filed 2024-11-14 | $8.77M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $3.23M 10-Q · filed 2024-08-08 | $5.61M 10-Q · filed 2024-08-08 | $7.53M derived: sum of 3 quarters · filed 2024-08-08 | $10.52M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.39M 10-Q · filed 2024-05-09 | $4.30M derived: sum of 2 quarters · filed 2024-05-09 | $7.30M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $4.91M derived: sum of 2 quarters · filed 2024-03-07 | $14.70M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $3.00M 10-Q · filed 2023-11-09 | $12.79M 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $4.34M 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $1.83M 10-K · filed 2022-03-10 | |||
| 2019-12-31 | $3.52M 10-K · filed 2021-03-11 | |||
| 2018-12-31 | $4.99M 10-K · filed 2020-03-12 | |||
| 2017-12-31 | $3.46M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |